IceCure Medical Ltd. announced that the FDA has granted marketing authorization for its ProSense cryoablation system for the ...
IceCure Medical announced today that the FDA granted marketing authorization for its ProSense cryoablation system for breast ...
"ProSense® offers the first new innovation in the treatment of women aged 70 and above with low-risk early-stage breast cancer in decades. We are proud to deliver a significant advancement and ...
MedPage Today on MSN
FDA Says Yes to Cryoablation for Early Breast Cancer
The FDA granted marketing authorization for the ProSense Cryoablation System for small, early-stage breast cancer in older ...
Icecure Medical Ltd. reported that the U.S. FDA has granted marketing authorization to Icecure's de novo application for the ...
Professor Eisuke Fukuma, who has performed over 600 breast cryoablation procedures, the majority of which were conducted with ProSense®, presented the latest data from his ongoing activity to treat ...
An update from Icecure Medical ( ($ICCM) ) is now available. On October 3, 2025, IceCure Medical announced that its ProSense® cryoablation system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback